AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17370489
Drug: Needle-pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-pricking therapy
Trial: 17370489
Drug: Medication (domiphen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (domiphen and HCG)
Trial: 11837987
Drug: Folic acid,
RxNorm normalized name: folic acid, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid, alone or in combination with vitamin B12 and vitamin B6
Trial: 9522322
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin (100 IU/day) with calcium supplementation (1000 mg/day)
Trial: 9522322
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg/day) with placebo intranasal spray
Trial: 8425809
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin lotion applied twice daily
Trial: 8425809
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks)
Trial: 3675694
Drug: Amoxicillin 1000
RxNorm normalized name: amoxicillin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg + ambroxol 60 mg t.i.d. (n = 8)
Trial: 3675694
Drug: Amoxicillin 1000
RxNorm normalized name: amoxicillin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg t.i.d. (n = 8)
Trial: 4950563
Drug: Typhoid vaccine
RxNorm normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid vaccine (control)
Trial: 25308804
Drug: Longer and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer and stronger post-induction therapy for T cell ME WBC patients
Trial: 25308804
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for B-ALL ME WBC patients
Trial: 25308804
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for patients with WBC <200 × 10(9) /l
Trial: 8389406
Drug: Liquid diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid diet with soluble fiber (21 g/L)
Trial: 2831114
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg once daily, doubled if BP not controlled after 4 weeks
Trial: 2831114
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP not controlled after 4 weeks
Trial: 30903459
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH), Fraxiparine (0.4 ml, 3800 IU/day) for 2 days
Trial: 30903459
Drug: Oral rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral rivaroxaban 10 mg/day for 2 days
Trial: 30903459
Drug: Oral rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral rivaroxaban 20 mg/day for 2 days
Trial: 28356142
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg (400 IU) of vitamin D3 supplementation
Trial: 28356142
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg (1200 IU) of vitamin D3 supplementation
Trial: 30735912
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg)
Trial: 14640934
Drug: 17 alpha‐progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha‐progesterone caproate (17P) 250 mg/week i.m.
Trial: 31397369
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment and human albumin (HA) infusions (40 g twice weekly for the first 2 weeks, then 40 g weekly for up to 18 months)
Trial: 31397369
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (SMT) alone
Trial: 31397369
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment and human albumin (HA) infusions
Trial: 24508841
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with gemcitabine and carboplatin (GC)
Trial: 22897339
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antiarrhythmic drug (AAD) in the first 3 months postablation
Trial: 20493783
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (OROS‐MPH) at doses of 18, 36, or 54 mg
Trial: 16002810
Drug: High-DHA algal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-DHA algal oil (approximately 200 mg DHA/d)
Trial: 12435860
Drug: rhEPO (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke
Trial: 12435860
Drug: rhEPO administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO administered within 5 hours of symptom onset
Trial: 2673316
Drug: Nicardipine 60
RxNorm normalized name: niCARdipine 60 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 60 mg twice daily for 4 weeks
Trial: 327942
Drug: Beclomethasone aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone aerosol given intranasally for 3 weeks (active drug)
Trial: 30916450
Drug: Multi-strategic memory
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strategic memory training (MMT) - 10 weekly 90-min sessions
Trial: 26105531
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP) treatment following accidental dural puncture (ADP)
Trial: 22496352
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) - either nicotine patch or nicotine gum for 5 weeks
Trial: 21752257
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (20 sessions over 30 weeks)
Trial: 21752257
Drug: Short Term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short Term Psychoanalytic Therapy (30 sessions over 30 weeks)
Trial: 19174696
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily with compliance-enhancing program
Trial: 19174696
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily without compliance-enhancing program
Trial: 19174696
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily with compliance-enhancing program in statin-naive patients
Trial: 19174696
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily without compliance-enhancing program in statin-naive patients
Trial: 17096684
Drug: Mizoribine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine 12 mg kg(‐1) day(‐1) (multiple-dose study)
Trial: 17096684
Drug: Mizoribine 3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine 3, 6, 9, and 12 mg kg(‐1) (single-dose study)
Trial: 17096684
Drug: Mizoribine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine 6 mg kg(‐1) day(‐1) once daily for 5 days (multiple-dose study)
Trial: 17096684
Drug: Mizoribine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine 12 mg kg(‐1) day(‐1) twice daily for 7 days (multiple-dose study)
Trial: 11696472
Drug: Intracoronary NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary NO synthase inhibition with N(G)‐monomethyl‐L‐arginine (L‐NMMA; 25 micromol/min)
Trial: 7781205
Drug: L-arginine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (160 mumol/min i.v. for 3 hours)
Trial: 2223361
Drug: Extradural administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural administration of methadone 5 mg
Trial: 666305
Drug: Cefadroxil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil (15 mg/kg)
Trial: 21197490
Drug: Group-bar (splinted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-bar (splinted mini-implants with a prefabricated bar)
Trial: 21197490
Drug: Group-ball (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-ball (two single ball-type mini-implants)
Trial: 15668556
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injection (40 mg of methylprednisolone acetate)
Trial: 14506619
Drug: MgC-Cre (Magnesium-creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgC-Cre (Magnesium-creatine chelate) at 800 mg Mg and 5 g Cre per day for 2 weeks
Trial: 14506619
Drug: MgO-Cre (Magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgO-Cre (Magnesium oxide plus creatine) at 800 mg Mg and 5 g Cre per day for 2 weeks
Trial: 10382900
Drug: Dirithromycin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (two 250 mg tablets od)
Trial: 6985742
Drug: iopronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopronic acid (4.5 g)
Trial: 6985742
Drug: iopanoic acid
RxNorm normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iopanoic acid (3.0 g)
Trial: 18835437
Drug: Typhoid vaccine
RxNorm normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid vaccine with psychological stress
Trial: 18835437
Drug: Typhoid vaccine
RxNorm normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid vaccine with rest
Trial: 7719221
Drug: Oral cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cancer patients with second cancers
Trial: 2439823
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg bopindolol
Trial: 2906897
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg bopindolol
Trial: 29338142
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion of 5 mL/h plus 5 mL demand bolus doses with 10-minute lockout (group B/D)
Trial: 29338142
Drug: Only demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only demand bolus doses of 5 mL with 10-minute lockout (group D)
Trial: 24010876
Drug: CS21 barrier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS21 barrier genital gel®
Trial: 21981375
Drug: Topical aciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aciclovir
Trial: 23107042
Drug: Metformin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (3 g daily)
Trial: 2868899
Drug: Ro 31-1118
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 31-1118 (10 mg)
Trial: 2868899
Drug: Ro 31-1118
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 31-1118 (20 mg)
Trial: 2868899
Drug: Ro 31-1118
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 31-1118 (40 mg)
Trial: 2868899
Drug: Ro 31-1118
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 31-1118 (80 mg)
Trial: 2868899
Drug: Ro 31-1118
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 31-1118 (all doses)
Trial: 27160412
Drug: THC:CBD oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC:CBD oromucosal spray
Trial: 24331983
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen/10 mg hydrocodone
Trial: 20642326
Drug: 0.5-g progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-g progesterone vaginal rings (PVR)
Trial: 20642326
Drug: 1-g progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-g progesterone vaginal rings (PVR)
Trial: 12590007
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 microg/day)
Trial: 14998844
Drug: Carboplatin 840
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy (60 Gy)
Trial: 12421891
Drug: Intranasal application
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal application of lysine aspirin for two weeks (5 patients)
Trial: 12421891
Drug: Intranasal application
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal application of lysine aspirin for six months (5 patients)
Trial: 7863253
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg/day for one year (Group A)
Trial: 7863253
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with nizatidine (Group B)
Trial: 31724170
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (administered every 2 weeks)
Trial: 31724170
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy with trastuzumab
Trial: 31724170
Drug: Standard-interval chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-interval chemotherapy (administered every 3 weeks)
Trial: 29998997
Drug: Yangyin Tiluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangyin Tiluo Decoction (YTD) for 4 weeks (200 mL of the decoction two times daily)
Trial: 20843496
Drug: Mail reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mail reminder group (letter plus CDC Influenza Vaccine Information Statement)
Trial: 16330297
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg IM single injection)
Trial: 16330297
Drug: Haloperidol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (7.5 mg IM single injection)
Trial: 16330297
Drug: Haloperidol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (7.5 mg IM multiple injections)
Trial: 16330297
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg IM multiple injections)
Trial: 11140808
Drug: l-carnitine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine (20 mg/kg)
Trial: 10051966
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan (6 mg)
Trial: 1946181
Drug: Alcohol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.0 g/kg)
Trial: 30526051
Drug: Brinzolamide-brimonidine fixed
RxNorm normalized name: brimonidine / brinzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide-brimonidine fixed combination
Trial: 25764777
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (neurodevelopmental rehabilitation and classic kinesiotherapy) plus botulinum toxin
Trial: 25764777
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (neurodevelopmental rehabilitation and classic kinesiotherapy)
Trial: 12791117
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose alone (BD) - pethidine 0.3 mg.kg‐1 loading dose and 150 micro g.kg‐1 bolus intravenously
Trial: 12791117
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose with background infusion (BD + BI) - pethidine 0.3 mg.kg‐1 loading dose, 75 micro g.kg‐1 bolus, and 15 micro g.kg‐1.h‐1 background infusion
Trial: 8968267
Drug: Diaspirin cross‐linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaspirin cross‐linked hemoglobin solution (100 mg/kg)
Trial: 8968267
Drug: Diaspirin cross‐linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaspirin cross‐linked hemoglobin solution (25 mg/kg)
Trial: 8968267
Drug: Diaspirin cross‐linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaspirin cross‐linked hemoglobin solution (50 mg/kg)
Trial: 8968267
Drug: Diaspirin cross‐linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaspirin cross‐linked hemoglobin solution
Trial: 29408444
Drug: Control (lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (lactated Ringer's solution)
Trial: 1298079
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg twice daily for two weeks
Trial: 26560899
Drug: PEH-MR 30-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEH-MR 30-mg modified-release tablets every 12 hours for 7 days
Trial: 26560899
Drug: PEH-MR 30-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEH-MR 30-mg modified-release tablets
Trial: 22050410
Drug: Buspirone 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 20-mg
Trial: 18562023
Drug: Coronary spasm
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary spasm group (sublingual nitroglycerin)
Trial: 18562023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sublingual nitroglycerin)
Trial: 16175767
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy (RSWT) - 2000 impulses, 4 weeks treatment
Trial: 16175767
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - 20 impulses of RSWT, 4 weeks treatment
Trial: 1989736
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol 2 mg
Trial: 1736698
Drug: Intravenous butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous butorphanol 2 mg
Trial: 6386593
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg intravenous infusion
Trial: 27378545
Drug: Parent present
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent present during dental treatment
Trial: 27378545
Drug: Parent absent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent absent during dental treatment
Trial: 27378545
Drug: Children's perception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's perception of their treatment
Trial: 22402934
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (SET) for PAD patients, duration of 3 weeks and 12 weeks, specific details on dosage not applicable.
Trial: 16139699
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15 s after 60 s etching of enamel and 20 s etching of dentin
Trial: 16139699
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15 s
Trial: 16139699
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 30 s
Trial: 16139699
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 45 s
Trial: 16139699
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system Adper Prompt L-Pop applied for 15, 30, and 45 s without pre-etching
Trial: 7511106
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg t.i.d.)
Trial: 12494049
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg o.d.)
Trial: 12494049
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no calcium antagonists)